Company Monitoring Page for Incyte

job ratings for Incyte

10/25/17
industry:
Biotech
company:
Incyte
job rating:
1
Great product, incompetent impotent leadership. No one at the wheel.
09/11/17
industry:
Biotech/Pharmaceutical
job title:
Sales
company:
Incyte
job rating:
3
Over regulated,incompetent management,

latest headlines for company on cafepharma

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Investors Business Daily
Mon, 03/17/25 - 10:14 pm
Tags:
Incyte, povorcitinib, clinical trials, hidradenitis suppurativa
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Fierce Biotech
Mon, 03/17/25 - 11:05 am
Tags:
Incyte, clinical trials, povorcitinib
Incyte exits immuno-oncology pact, leaving Agenus weighing options for assets
Fierce Biotech
Tue, 02/11/25 - 11:28 am
Tags:
Incyte, immuno-oncology, Agenus
Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams
Fierce Pharma
Mon, 02/10/25 - 10:27 pm
Tags:
Incyte, Opzelura, Jakafi
JPM25: Incyte plans to turn 'a lot of cards' in 2025 as CEO eyes 2 types of deals
Fierce Pharma
Wed, 01/22/25 - 07:24 pm
Tags:
JPMHC 2025, Pharma CEOs, Incyte, Hervé Hoppenot
Incyte scraps anemia program after drug fails to improve symptoms in rare blood cancer
Fierce Biotech
Sun, 12/15/24 - 10:46 pm
Tags:
Incyte, myelofibrosis, anemia, zilurgisertib
Incyte sinks on setback for drugs acquired in $750M buyout
BioPharma Dive
Tue, 11/19/24 - 07:10 pm
Tags:
Incyte, Escient Pharma, M&A
Incyte blocks US launch of Sun Pharma's alopecia drug
Pharmaphorum
Mon, 11/4/24 - 11:10 am
Tags:
Incyte, Sun Pharma, Leqselvi, alopecia areata
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Fierce Pharma
Wed, 10/30/24 - 11:42 am
Tags:
Incyte, Jakafi, patent cliff, Niktimvo, graft vs host disease, Monjuvi, follicular lymphoma, Zynyz, squamous cell anal carcinoma
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Fierce Pharma
Sun, 09/15/24 - 06:27 pm
Tags:
Incyte, Zynyz, ESMO
Incyte and Syndax's immunotherapy for transplant complications receives FDA approval
Biopharma Reporter
Tue, 08/20/24 - 11:49 am
Tags:
Incyte, Syndax, immunotherapy, Niktimvo, graft vs host disease
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
Clinical Trials Arena
Fri, 08/16/24 - 11:19 am
Tags:
Incyte, clinical trials, Monjuvi, relapsed or refractory follicular lymphoma
FDA approves Incyte's treatment for chronic graft-versus-host disease
Reuters
Wed, 08/14/24 - 10:37 pm
Tags:
Incyte, FDA, graft vs host disease, Niktimvo
Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year
Fierce Biotech
Tue, 07/30/24 - 11:44 am
Tags:
Incyte, anti-PD-L1
Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state
Fierce Pharma
Tue, 05/21/24 - 06:56 pm
Tags:
Incyte, Delaware, Opzelura
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
BioSpace
Tue, 04/23/24 - 09:46 pm
Tags:
Incyte, M&A, Escient Pharma, atopic dermatitis
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Fierce Biotech
Mon, 03/11/24 - 11:52 am
Tags:
Incyte, clinical trials, prurigo nodularis, povorcitinib, Dupixent, Sanofi, Regeneron
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Tags:
Synnovation Therapeutics, Incyte, AstraZeneca, GSK, Novartis, Pfizer, funding, cancer, PARP inhibitors
Incyte reports positive data from Phase III vitiligo trial
Clinical Trials Arena
Thu, 10/12/23 - 05:27 pm
Tags:
Incyte, Opzelura, vitiligo, clinical trials
Replimune and Incyte to study cancer combo therapy in CSCC patients
Clinical Trials Arena
Tue, 08/1/23 - 10:06 am
Tags:
Replimmune, Incyte, clinical trials, RP1, CSCC, cutaneous squamous cell carcinoma

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.